Form 8-K - Current report:
SEC Accession No. 0001104659-25-034755
Filing Date
2025-04-15
Accepted
2025-04-14 17:36:32
Documents
14
Period of Report
2025-04-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FROM 8-K tm2512256d1_8k.htm   iXBRL 8-K 39382
2 EXHIBIT 2.1 tm2512256d1_ex2-1.htm EX-2.1 20849
  Complete submission text file 0001104659-25-034755.txt   243225

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ckpt-20250414.xsd EX-101.SCH 3026
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ckpt-20250414_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ckpt-20250414_pre.xml EX-101.PRE 22366
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2512256d1_8k_htm.xml XML 3688
Mailing Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453
Business Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453 781-652-4500
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

EIN.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38128 | Film No.: 25836916
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)